{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:23Z","timestamp":1774656023418,"version":"3.50.1"},"reference-count":89,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.vaccine.2015.09.079","type":"journal-article","created":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T09:20:30Z","timestamp":1444036830000},"page":"6545-6551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Is immunotherapy an opportunity for effective treatment of drug addiction?"],"prefix":"10.1016","volume":"33","author":[{"given":"Jadwiga","family":"Zalewska-Kaszubska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.09.079_bib0450","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1586\/14760584.3.1.11","article-title":"Therapeutic vaccines for substance dependence","volume":"3","author":"Haney","year":"2004","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0455","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pharmthera.2005.06.009","article-title":"Immunotherapy for the treatment of drug abuse","volume":"108","author":"Kosten","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0460","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/1570163043484851","article-title":"Development of immunopharmacotherapy against drugs of abuse","volume":"1","author":"Meijler","year":"2004","journal-title":"Curr Drug Discov Technol"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0465","doi-asserted-by":"crossref","first-page":"95","DOI":"10.20882\/adicciones.101","article-title":"Advances in the development of biologics to treat drug addictions and overdose","volume":"24","author":"Montoya","year":"2012","journal-title":"Adicciones"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0470","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2011.281","article-title":"Vaccines against drug abuse","volume":"91","author":"Shen","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0475","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0264-410X(01)00425-X","article-title":"Human therapeutic cocaine vaccine: safety and immunogenicity","volume":"20","author":"Kosten","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0480","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/eji.200526285","article-title":"A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity","volume":"35","author":"Maurer","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0485","doi-asserted-by":"crossref","first-page":"e2547","DOI":"10.1371\/journal.pone.0002547","article-title":"A vaccine against nicotine for smoking cessation: a randomized controlled trial","volume":"3","author":"Cornuz","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0490","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.biopsych.2005.04.032","article-title":"Vaccine pharmacotherapy for the treatment of cocaine dependence","volume":"58","author":"Martell","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0495","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1196\/annals.1441.027","article-title":"Substance abuse vaccines","volume":"1141","author":"Orson","year":"2008","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0500","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0091-3057(99)00206-3","article-title":"A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuate its behavioral and cardiovascular effect in rats","volume":"65","author":"Pentel","year":"2000","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0505","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1586\/erv.13.1","article-title":"Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse","volume":"12","author":"Brimijoin","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0510","doi-asserted-by":"crossref","first-page":"876","DOI":"10.2174\/187152711799219352","article-title":"Immunotherapy for drug abuse","volume":"10","author":"Shen","year":"2011","journal-title":"CNS Neurol. Disord Drug Targets"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0515","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00213-010-2040-3","article-title":"Effects of cocaine hydrolase on cocaine self-administration under a PR schedule and during extended access (escalation) in rats","volume":"213","author":"Carroll","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0520","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/clpt.2010.155","article-title":"Anti-(+) methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction","volume":"88","author":"Gentry","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0525","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4155\/fmc.09.20","article-title":"Recent progress in protein drug design and discovery with a focus on novel approaches to the development of anti-cocaine medications","volume":"1","author":"Zheng","year":"2009","journal-title":"Future Med Chem"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0530","doi-asserted-by":"crossref","first-page":"667","DOI":"10.4049\/jimmunol.110.3.667","article-title":"A measurement of the specificities of antibodies to morphine-6-succinyl-BSA by competitive inhibition of 14 C-morphine binding","volume":"110","author":"Wainer","year":"1973","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0535","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/252708a0","article-title":"Changes in heroin self-administration by a rhesus monkey after morphine immunisation","volume":"252","author":"Bonese","year":"1974","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0540","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0091-3057(78)90295-2","article-title":"Effects of passive immunization against morphine on heroin self-administration","volume":"9","author":"Killian","year":"1978","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0545","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.112.201194","article-title":"Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats","volume":"344","author":"Raleigh","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0550","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2174\/187152711799219316","article-title":"Developing a vaccine against multiple psychoactive targets: a case study of heroin","volume":"10","author":"Stowe","year":"2011","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0555","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1016\/j.vaccine.2006.01.047","article-title":"A novel bivalent morphine\/heroin vaccine that prevents relapse to heroin addiction in rodents","volume":"24","author":"Anton","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0560","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1471-4159.2011.07502.x","article-title":"A morphine\/heroin vaccine with new hapten design attenuates behavioral effects in rats","volume":"119","author":"Li","year":"2011","journal-title":"J Neurochem."},{"key":"10.1016\/j.vaccine.2015.09.079_bib0565","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1016\/j.vaccine.2012.04.101","article-title":"Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats","volume":"30","author":"Pravetoni","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0570","doi-asserted-by":"crossref","first-page":"9036","DOI":"10.1073\/pnas.1219159110","article-title":"Dynamic vaccine blocks relapse to compulsive intake of heroin","volume":"110","author":"Schlosburg","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0575","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s002130050049","article-title":"Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model","volume":"148","author":"Kantak","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0580","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s002130000555","article-title":"Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010","volume":"53","author":"Kantak","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0585","first-page":"1070","article-title":"TA-CD. Xenova","volume":"5","author":"Heading","year":"2002","journal-title":"IDrugs"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0590","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1001\/archgenpsychiatry.2009.128","article-title":"Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial","volume":"66","author":"Martell","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0595","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1521-0391.2013.00314.x","article-title":"Spontaneous development of IgM anti-cocaine antibodies in habitual cocaine users: effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine","volume":"22","author":"Orson","year":"2013","journal-title":"Am J Addict"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0600","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neulet.2013.02.037","article-title":"DBH gene as predictor of response in a cocaine vaccine clinical trial","volume":"541","author":"Kosten","year":"2013","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0605","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.drugalcdep.2014.04.003","article-title":"Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial","volume":"140","author":"Kosten","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0610","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/mt.2010.280","article-title":"Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs","volume":"19","author":"Hicks","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0615","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/npp.2011.200","article-title":"Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects","volume":"37","author":"Wee","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0620","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1038\/npp.2013.114","article-title":"Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter","volume":"38","author":"Maoz","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0625","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.biopsych.2009.08.031","article-title":"Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans","volume":"67","author":"Haney","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0630","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1021\/mp200588v","article-title":"An antidote for acute cocaine toxicity","volume":"9","author":"Treweek","year":"2012","journal-title":"Mol Pharm"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0635","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2217\/imt.12.19","article-title":"Predicting the clinical efficacy and potential adverse effects of a humanized anticocaine monoclonal antibody","volume":"4","author":"Norman","year":"2012","journal-title":"Immunotherapy"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0640","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0022-3565(24)39014-7","article-title":"Natural and artificial enzymes against cocaine I. Monoclonal antibody 15A10 and the reinforcing effects of cocaine in rats","volume":"295","author":"Baird","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0645","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1021\/jm400228w","article-title":"Probing active cocaine vaccination performance through catalytic and noncatalytichapten design","volume":"56","author":"Cai","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0650","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0022-1759(02)00237-5","article-title":"Anticocaine catalytic antibodies","volume":"269","author":"Deng","year":"2002","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0655","doi-asserted-by":"crossref","first-page":"10176","DOI":"10.1073\/pnas.95.17.10176","article-title":"A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats","volume":"95","author":"Mets","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0660","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S1567-5769(01)00054-6","article-title":"A catalytic antibody against cocaine attenuates cocaine's cardiovascular effects in mice: a dose and time course analysis","volume":"1","author":"Briscoe","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0665","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/02791072.2000.10400231","article-title":"Predictors of relapse after treatment for methamphetamine use","volume":"32","author":"Brecht","year":"2000","journal-title":"J Psychoactive Drugs"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0670","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/j.1360-0443.2009.02564.x","article-title":"A review of the clinical pharmacology of methamphetamine","volume":"104","author":"Cruickshank","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0675","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1080\/09595230801935672","article-title":"A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal","volume":"27","author":"Cruickshank","year":"2008","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0680","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1016\/j.vaccine.2009.02.105","article-title":"Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines","volume":"27","author":"Duryee","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0685","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1021\/ja108807j","article-title":"Impact of distinct chemical structures for the development of a methamphetamine vaccine","volume":"133","author":"Moreno","year":"2011","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0690","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.biopsych.2012.09.010","article-title":"A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats","volume":"73","author":"Miller","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2015.06.014","article-title":"Effects of active anti-methamphetamine vaccination on intravenous self-administration in rats","author":"Miller","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0700","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.drugalcdep.2012.09.007","article-title":"A vaccine against methamphetamine attenuates its behavioral effects in mice","volume":"129","author":"Shen","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0705","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1016\/j.vaccine.2013.07.038","article-title":"Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food","volume":"31","author":"R\u00fcedi-Bettschen","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0710","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4161\/mabs.27620","article-title":"Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use","volume":"6","author":"Stevens","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0715","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.4161\/hv.29707","article-title":"Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development","volume":"10","author":"Laurenzana","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0720","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.4161\/19420862.2014.976431","article-title":"First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers","volume":"6","author":"Stevens","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0725","first-page":"CD009329","article-title":"Pharmacological interventions for smoking cessation: an overview and network meta-analysis","volume":"5","author":"Cahill","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0730","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0192-0561(00)00042-4","article-title":"Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain","volume":"22","author":"Hieda","year":"2000","journal-title":"Int J Immunopharmacol"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0735","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000063629","article-title":"Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats","volume":"69","author":"Lindblom","year":"2002","journal-title":"Respiration"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0740","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev.pharmtox.48.113006.094742","article-title":"Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics","volume":"49","author":"Benowitz","year":"2009","journal-title":"Ann Re Pharmacol Toxicol"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0745","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMra0809890","article-title":"Nicotine addiction","volume":"362","author":"Benowitz","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0750","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1385\/JMN:30:1:181","article-title":"CNS localization of neuronal nicotinic receptors","volume":"30","author":"Nashmi","year":"2006","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0755","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/hmg\/ddn181","article-title":"Pharmacogenetics of nicotine addiction and treatment consortium: nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation","volume":"17","author":"Conti","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0760","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature03694","article-title":"Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors","volume":"436","author":"Maskos","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0765","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/34413","article-title":"Acetylcholine receptors containing the \u03b22 subunit are involved in the reinforcing properties of nicotine","volume":"391","author":"Picciotto","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0770","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1176\/appi.ajp.2012.12060793","article-title":"Effect of a nicotine vaccine on nicotine binding to \u03b22*-nicotinic acetylcholine receptors in vivo in human tobacco smokers","volume":"170","author":"Esterlis","year":"2013","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0775","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.clpt.2005.08.007","article-title":"Safety and immunogenicity of a nicotine conjugate vaccine in current smokers","volume":"78","author":"Hatsukami","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0780","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/14622200701704921","article-title":"The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1\/2 trial","volume":"10","author":"Wagena","year":"2008","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0785","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.2010.317","article-title":"Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic","volume":"89","author":"Hatsukami","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0790","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1586\/erv.13.13","article-title":"Therapeutic vaccines against tobacco addiction","volume":"12","author":"Fahim","year":"2013","journal-title":"CNS Neurol Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0795","unstructured":"Nabi Biopharmaceuticals: News Release. Nabi Biopharmaceuticals Announces Results of Second NicVAX(R) Phase III Clinical Trial. http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=100445&p=irol-newsArticle&ID=1626882"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0800","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/add.12573","article-title":"Efficacy of the nicotine vaccine 3\u2032-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: a randomized placebo-controlled trial","volume":"109","author":"Hoogsteder","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0805","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/add.12577","article-title":"Treatment with a nicotine vaccine does not lead to changes in brain activity during smoking cue exposure or a working memory task","volume":"109","author":"Havermans","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0810","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/ntr\/ntt003","article-title":"Niccine\u00ae, a nicotine vaccine, for relapse prevention: a phase II, randomized, placebo-controlled, multicenter clinical trial","volume":"15","author":"Tonstad","year":"2013","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0815","unstructured":"Selecta Biosciences Recent news. Selecta Biosciences Initiates Phase 1 Clinical Study of SEL-068, a First-in-Class Synthetic Nicotine Vaccine for Smoking Cessation and Relapse Prevention \u3008http:\/\/www.selectabio.com\/news\/recent-news\/Selecta-Biosciences-Initiates-Phase-1-Clinical-Study-of-SEL-068.cfm\u3009."},{"key":"10.1016\/j.vaccine.2015.09.079_bib0820","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1016\/j.vaccine.2013.10.051","article-title":"Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum","volume":"31","author":"De Villiers","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0825","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1089\/hum.2012.245","article-title":"Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine","volume":"24","author":"Rosenberg","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0830","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4161\/hv.26635","article-title":"A novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicle","volume":"10","author":"Hu","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0835","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.intimp.2011.07.009","article-title":"Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy","volume":"11","author":"Cornish","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0840","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1124\/jpet.107.135111","article-title":"Combined active and passive immunization enhances the efficacy of immunotherapy against nicotine in rats","volume":"325","author":"Roiko","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0845","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/schbul\/sbs011","article-title":"Phencyclidine\/schizophrenia: one view toward the past, the other to the future","volume":"38","author":"Domino","year":"2012","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0850","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0090-9556(25)08275-3","article-title":"Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs","volume":"14","author":"Owens","year":"1986","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0855","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0022-3565(25)20655-3","article-title":"Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats","volume":"278","author":"Valentine","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0860","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0022-3565(25)20654-1","article-title":"Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats","volume":"278","author":"Valentine","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0865","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0022-3565(24)35360-1","article-title":"Anti-phencyclidine monoclonal antibodies provide longterm reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats","volume":"292","author":"Proksch","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0870","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1124\/jpet.302.1.119","article-title":"A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats","volume":"302","author":"Hardin","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0875","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1124\/dmd.105.005934","article-title":"Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted","volume":"34","author":"Pitas","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0880","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1124\/jpet.103.053140","article-title":"Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody","volume":"306","author":"Laurenzana","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0885","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.intimp.2007.09.020","article-title":"Engineering and characterization of a mouse\/human chimeric anti-phencyclidine monoclonal antibody","volume":"8","author":"Lacy","year":"2008","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vaccine.2015.09.079_bib0890","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.intimp.2011.09.016","article-title":"Chronic anti-phencyclidine monoclonal antibody therapy decreases phencyclidine-induced in utero fetal mortality in pregnant rats","volume":"11","author":"Hubbard","year":"2011","journal-title":"Int Immunopharmacol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15013699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15013699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T22:32:09Z","timestamp":1748644329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15013699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":89,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0264410X15013699"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.09.079","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is immunotherapy an opportunity for effective treatment of drug addiction?","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.09.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}